1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ambalal Sarabhai Enterprises Limited

Ambalal Sarabhai Enterprises Limited

36.44
INR
-0.21
(-0.57%)
1.75EPS
19.52P/E
2.51BMarket Cap
Ambalal Sarabhai Enterprises Limited
NSE:AMBALALSA
(National Stock Exchange of India)

Recent

price

36.44

P/E

ratio

19.52

div

yld

- -

ROIC.AI

2009
2010
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
10.99
9.81
13.08
13.66
16.25
17.22
17.47
16.19
19.67
17.06
21.19
25.43
22.14
22.57
25.49
26.23
26.56
Revenue per Share
0.93
-0.03
-2.39
-2.64
-0.87
6.28
-2.38
0.17
0.55
1.83
3.83
6.16
1.49
0.74
0.64
2.32
1.68
Basic EPS, GAAP
-14.92
-4.17
-0.62
1.26
-1.39
-11.62
0.04
-2.47
1.1
-1.38
-0.62
-0.55
-1.95
0.78
-2.65
0.96
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.3
7.23
2.34
-0.28
-1.23
5.78
3.28
3.46
4
5.84
9.64
15.64
17.08
17.8
18.27
20.66
- -
Book Value per Share
1.55
1.48
-2.47
-5.12
-6.05
2.48
0.04
0.24
0.78
2.63
6.44
12.44
13.88
14.6
15.07
17.23
- -
Tangible Book Value per Share
77
77
77
77
77
77
77
77
77
77
77
77
77
77
77
77
77
Basic Weighted Avg Shares
842
752
1,002
1,047
1,245
1,320
1,339
1,241
1,508
1,307
1,624
1,949
1,696
1,729
1,953
2,010
2,055
Sales/Revenue/Turnover
-139.48
-27.36
-9.65
-9.25
-6.37
-20.13
-7.35
-9.82
4.59
-1.87
3.65
12.2
4.16
3.03
4.73
8.1
6.05
Operating Margin (%)
22
27
140
30
48
165
43
21
21
26
24
23
28
36
40
39
44
Depreciation Expense
71
-3
-183
-202
-67
481
-182
13
42
141
294
472
114
57
49
178
130
Net Income, GAAP
58.46
105.33
- -
- -
- -
22.04
- -
84
48.3
5.88
9.79
12.87
24.55
14.59
- -
3.8
11.12
Effective Tax Rate (%)
8.49
-0.34
-18.28
-19.31
-5.36
36.47
-13.61
1.03
2.82
10.76
18.07
24.23
6.75
3.28
2.52
8.86
6.32
Profit Margin (%)
-425
-421
-705
-871
-944
-397
-512
-419
-551
-295
-80
147
81
162
-19
265
- -
Working Capital
88
142
41
32
58
48
51
111
88
49
54
34
113
98
90
218
- -
LT Debt
560
554
179
-22
-94
443
252
265
306
448
739
1,199
1,309
1,364
1,400
1,584
- -
Total Equity
- -
-0.38
- -
- -
- -
78.66
- -
0.51
5.02
-3.11
22.24
26.94
3.11
2.55
- -
7.48
- -
Return on Invested Capital (%)
- -
-0.54
- -
- -
- -
80.43
- -
2.64
8.41
23.3
35.86
39.19
8.21
5.88
- -
10.7
- -
Return on Capital (%)
- -
-0.46
-49.96
- -
- -
- -
-52.49
4.94
14.87
37.3
49.48
48.74
9.13
4.25
3.57
11.94
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
347
- -
LT Borrowings
- -
177
- -
LT Finance Leases
- -
42
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
77
77
77
Market Capitalization
- -
- -
2,510

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,250
- -
Cash, Cash Equivalents & STI
- -
166
- -
Accounts Receivable, Net
- -
477
- -
Inventories
- -
222
- -
Total Current Liabilities
- -
985
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
347
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.03%
18.28%
13.13%
Free Cash Flow
-689.84%
-94.97%
-136.07%
Net Income, GAAP
51.01%
36.51%
261.05%
Sales/Revenue/Turnover
5.14%
4.96%
2.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
407
447
500
648
1,953
2026
470
444
520
655
2,010
2027
436
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.05
0.34
0.29
-0.03
0.64
2026
1.07
-0.07
0.4
0.85
2.32
2027
0.52
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ambalal Sarabhai Enterprises Limited (ASE), founded in 1977 and headquartered in Ahmedabad, India, serves as a holding company overseeing a diversified group of subsidiaries engaged in pharmaceuticals, molecular diagnostics, and electronics manufacturing; it markets and produces active pharmaceutical ingredients including niche fermentation-based amphotericin B through Synbiotics, coated ascorbic acid (Vitamin C) via Sarabhai M Chemicals, oncology and infertility treatments under the Sarabhai brand through Sarabhai Chemicals, branded and generic pharmaceuticals plus veterinary products via Suvik Hitek, effervescent formulations at Vovantis Laboratories' USFDA-approved facility targeting US and European markets, export-oriented formulations at Asence Pharma Pvt Ltd, PCR-based molecular diagnostics through CoSara in partnership with Co-Diagnostics USA, precision testing and measurement instruments via Systronics, and professional audio/video broadcasting equipment through Telerad; operations span India and international markets with key technologies in synthetic chemistry for APIs, effervescent solutions, fermentation, and scientific instrumentation. Recent developments include the National Company Law Tribunal's approval on October 25, 2024, for the demerger of oncology and profertility divisions from Sarabhai Chemicals into Asence Pharma Private Limited; a marketing tie-up with an external firm to enhance sales; expansion of Vitamin C coated products manufacturing at Sarabhai M Chemicals; launch of a rapid diagnostics product range in 2023; and a major expansion or diversification announcement in November 2024 alongside boosted focus on Vovantis' effervescent exports.